Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)
Klinische Pädiatrie | December 3, 2025 | Volume: 237 | Issue: No issue available | Pages: No page available
10.1055/s-0045-1812988